Dexmedetomidine ameliorates TNBS induced colitis by inducing immunomodulator effect

Basit Öğe Kaydı
dc.authorid41809en_US
dc.contributor.authorErdoğan Kayhan, Gülay
dc.contributor.authorGül, Mehmet
dc.contributor.authorKayhan, Başak
dc.contributor.authorGedik, Ender
dc.contributor.authorÖzgül, Ülkü
dc.contributor.authorKurtoğlu, Elçin Latıfe
dc.contributor.authorDurmuş, Mahmut
dc.contributor.authorErsoy, Mehmet Özcan
dc.date.accessioned2017-08-01T07:29:31Z
dc.date.available2017-08-01T07:29:31Z
dc.date.issued2013
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground: Since sedatives are often administered to immune-compromised and critically ill patients, our understanding of immunomodulation by sedation will be critical. Dexmedetomidine, a selective a2-adrenergic receptor agonist, is often used for sedation and analgesia especially in intensive care units. There are conflicting and little data concerning both the effect and the mechanism of dexmedetomidine on immune response. In our study, we aimed to investigate the effect of dexmedetomidine on immune system at two different doses (5 mg.kg 1 and 30 mg.kg 1 ) during inflammatory bowel disease by using an experimental model, which resembles both systemic and local inflammation. Methods: The effect of dexmedetomidine on the course of inflammatory bowel disease was investigated by measuring macroscopic and microscopic parameters. We investigated proinflammatory Th1, Th2, and Th17 cytokine levels in serum samples to analyze systemic immune response. Following this, local immune response was investigated by measuring cytokine levels in the presence of dexmedetomidine in spleen cell culture. Results: Dexmedetomidine administration led to amelioration of all disease associated pathological manifestations. According to our in vitro and in vivo results, dexmedetomidine shows anti-inflammatory effect by increasing IL-4 and IL-10 levels responsible from antiinflammatory response via Th2 pathway. Moreover, we showed for the first time in the study that dexmedetomidine administration reduces IL-23, which is responsible from initiation of inflammatory response via Th17 pathway. Conclusions: Dexmedetomidine can have beneficial effect on preoperative or postoperative inflammatory bowel disease patients in intensive care units by down-regulating inflammatory immune response not only in systemic circulation but also in tissue-specific manner.en_US
dc.identifier.citationErdoğan Kayhan, G. Gül, M. Kayhan, B. Gedik, E. Özgül, Ü. Kurtoğlu, E. L. Durmuş, M. Ersoy, M. Ö. (2013). Dexmedetomidine ameliorates TNBS induced colitis by inducing immunomodulator effect. Journal of Surgical Research, 183(2), 733–741.en_US
dc.identifier.doi10.1016/j.jss.2013.03.028en_US
dc.identifier.endpage741en_US
dc.identifier.issn00224804
dc.identifier.issue2en_US
dc.identifier.startpage733en_US
dc.identifier.urihttp://linkinghub.elsevier.com/retrieve/pii/S0022480413002230
dc.identifier.urihttps://hdl.handle.net/11616/7428
dc.identifier.volume183en_US
dc.language.isoenen_US
dc.publisherJournal of Surgical Researchen_US
dc.relation.ispartofJournal of Surgical Researchen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectInflammatory bowel diseasesen_US
dc.subjectDexmedetomidineen_US
dc.subjectImmune responseen_US
dc.subjectCytokinesen_US
dc.titleDexmedetomidine ameliorates TNBS induced colitis by inducing immunomodulator effecten_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Makale Dosyası.pdf
Boyut:
1.45 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.71 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Tıp Fakültesi, Tıbbi Biyoloji ve Genetik Anabilim Dalı Koleksiyonu